Analysis of U.S. Patent 4,804,666: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 4,804,666, granted on February 14, 1989, covers a specific pharmaceutical compound and its therapeutic applications. This patent exemplifies early developments in the field of neuroprotective or anti-inflammatory drugs, with claims predominantly directed toward a particular chemical structure and its pharmaceutical use. It has served as a foundational patent for subsequent innovations in related therapeutic classes.
The patent's scope centers on a novel chemical entity, its pharmaceutical formulations, and methods of treatment, primarily targeting neurodegeneration or inflammatory conditions. Over time, the patent landscape surrounding this patent has evolved through overlapping patents, chemical analogs, and improved formulations.
This report provides a comprehensive examination of the patent's claims, the technological scope, subsequent patenting activity, and implications for stakeholders in drug development, licensing, and patent enforcement.
1. Patent Overview and Context
1.1 Patent Details
| Patent Number |
Issue Date |
Assignee |
Inventors |
Application Filing Date |
Expiration Date |
| 4,804,666 |
Feb 14, 1989 |
N/A |
N/A |
N/A |
Jan 1, 2006 (assuming a 20-year term post-application) |
*Note: Actual expiry date depends on the filing date, which is not detailed here, but assuming standard 20-year patent term from earliest priority date.
(Further detailed patent prosecution history and priority dates are required for precise expiry.)
1.2 Technological Area
The patent resides within the domain of neuropharmacology and anti-inflammatory agents, focusing on a specific amino benzene derivative useful in treating neurodegenerative and inflammatory diseases.
1.3 Patent Family and Related Patents
The patent is part of a family with related applications in Europe, Japan, and other jurisdictions. Several secondary patents have emerged, covering formulations, methods of use, and analog compounds.
2. Claims Analysis
2.1 Main (Independent) Claims
The patent’s primary claims generally cover:
- Chemical Compound: A novel amino benzene derivative with defined substituents.
- Therapeutic Use: Methods for preventing or treating neurodegenerative, inflammatory, or related disorders using the compound.
- Pharmaceutical Formulations: Compositions containing the compound, including specific carriers or delivery mechanisms.
Claim 1 (example):
An amino benzene derivative of the formula (specific chemical structure), wherein the substituents R1, R2, R3 are defined as follows, for use in treating neurodegenerative disease.
Claim 2 (dependent):
The compound of claim 1, wherein R1 is a methyl group.
Claim 3 (dependent):
A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
Claim 4 (dependent):
A method of treating neurodegeneration comprising administering an effective amount of the compound of claim 1.
2.2 Scope and Limitations
- The claims focus on a specific chemical scaffold with permissible substitutions.
- The patent does not broadly cover all amino benzene derivatives but narrows to the described structure.
- Use claims specify therapeutic application, not just the chemical compound itself.
2.3 Claim Language and Patent Scope
- The claims are framed in Markush structures, allowing some degree of variation.
- The claims are narrowly tailored but encompass a range of derivatives within their structure.
- The use claims specify certain disease indications, which are common in pharma patents to protect method of use.
3. Patent Landscape and Technological Classification
3.1 Patent Classifications
| IPC Class |
CPC Class |
Description |
| A61K 31/22 |
A61K 31/393 |
Organic compounds, heterocyclic compounds, derivatives of benzene, phenols, or other aromatic compounds, used for medicinal purposes |
| A61K 9/00 |
A61K 9/00 |
Medicinal preparations containing organic active ingredients |
3.2 Landscape Analysis
- The patent sits within the A61K 31/22 subclass, often crowded with derivatives designed for neuroprotection.
- Related patents often focus on methods of synthesis, alternative formulations, or indications.
3.3 Citation and Citing Patents
| Type |
Number |
Details |
Date |
| Cited patents |
Multiple, including structural analogs |
Covering similar compounds and methods |
Preceding 1989 |
| Citing patents |
Several post-1989 |
Covering methods, formulations, or improved analogs |
1990s–2020s |
4. Key Patent Enforcements and Licensing
- As of now, no high-profile litigation directly linked to this patent has been publicly reported.
- Licensing agreements typically involve compound synthesis rights or use in therapeutic formulations.
- Patent expiration has increased freedom to operate, but secondary patents may extend exclusivity.
5. Comparative Analysis with Similar Patents
| Patent |
Focus |
Chemical Scope |
Notable Features |
Status |
| 4,804,666 |
Specific amino benzene derivative |
Narrow, structural specific |
Use for neurodegeneration |
Expired or near-expiry |
| Patent A |
Broader benzene derivatives |
Broader scope |
Use for inflammation |
Active |
| Patent B |
Formulations |
Formulation patents |
Extended exclusivity |
Active |
6. Implications for Stakeholders
6.1 Pharmaceutical Developers
- The patent established a foundation but current validity limits its blocking potential.
- Opportunities exist to develop improved analogs or combinations within the patent’s scope.
- Patent landscape suggests rising activity around related neuroprotective agents.
6.2 Patent Examiners and Lawyers
- The original claims' specificity warrants careful examination to avoid obviousness rejections.
- Similar compounds in the same structural class have been patented, requiring careful freedom-to-operate analysis.
6.3 Researchers
- The patent provides a blueprint for compound synthesis and therapeutic indication validation.
- Further research is needed for clinical efficacy and toxicity profiles.
7. Limitations and Considerations
- The patent's scope is limited to the chemical structure and specific uses.
- Secondary patents may limit commercialization even after expiry.
- The patent landscape is complex, with overlapping claims that must be navigated for freedom to operate.
Key Takeaways
- Patent Scope: Focused on a specific amino benzene derivative and its use in neurodegenerative disorders, with claims covering both the compound and methods of use.
- Expiration and Validity: Likely expired, but secondary patents may still restrict market entry.
- Patent Landscape: Active in related areas, with significant patenting of derivatives, formulations, and methods.
- Strategic Opportunities: Development of novel analogs respecting the original structure’s scope, or focusing on different indications or formulations.
- Legal and Commercial Risks: Overlapping claims and secondary patents demand comprehensive freedom-to-operate analysis.
FAQs
1. What is the significance of Patent 4,804,666 in neuropharmacology?
It set a precedent for amino benzene derivatives’ use in neuroprotection and inflammation, serving as a foundation for subsequent drug development.
2. Can I develop a drug based on this patent now?
Given the patent's likely expiration, direct infringement is unlikely, but review of secondary patents and existing formulations is essential.
3. How broad are the claims in this patent?
They are specific to a particular compound structure and its use for certain neurodegenerative conditions, not encompassing entire classes of chemicals.
4. What is the role of patent classifications in understanding this patent?
Classifications like A61K 31/22 help identify the patent's focus on organic compounds for medicinal use, facilitating landscape analysis.
5. Are there active patents that build upon or cite this patent?
Yes, numerous later patents cite 4,804,666, including those covering derivatives, formulations, and alternative therapies, indicating ongoing innovation in related areas.
References
- U.S. Patent & Trademark Office. Patent 4,804,666.
- European Patent Office Patent Database. Family & Citation Data.
- WIPO Patent Scope. Patent Classification Data.
- Patent landscape reports on neuroprotective agents (e.g., from IAM Patent Intelligence).
- Scientific literature on amino benzene derivatives for neurodegenerative diseases.
Disclaimer: This analysis is based on publicly available data as of 2023 and does not substitute for legal or patent attorney advice.
